Ge Xinyuan, Zhang Lu, Liu Maojie, Wang Xiao, Xu Xin, Yan Yuqian, Tian Chan, Yang Juan, Ding Yang, Yu Chengxiao, Lu Jing, Jiang Longfeng, Wang Qiang, Zhang Qun, Song Ci
Department of Epidemiology, China International Cooperation Center on Environment and Human Health, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China.
The Dumont-UCLA Transplant Center, Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
J Clin Transl Hepatol. 2024 Jun 28;12(6):562-570. doi: 10.14218/JCTH.2023.00575. Epub 2024 May 28.
Age-related mosaic chromosomal alterations (mCAs) detected from genotyping of blood-derived DNA are structural somatic variants that indicate clonal hematopoiesis. This study aimed to investigate whether mCAs contribute to the risk of cirrhosis and modify the effect of a polygenic risk score (PRS) on cirrhosis risk prediction.
mCA call sets of individuals with European ancestry were obtained from the UK Biobank. The PRS was constructed based on 12 susceptible single-nucleotide polymorphisms for cirrhosis. Cox proportional hazard models were applied to evaluate the associations between mCAs and cirrhosis risk.
Among 448,645 individuals with a median follow-up of 12.5 years, we identified 2,681 cases of cirrhosis, 1,775 cases of compensated cirrhosis, and 1,706 cases of decompensated cirrhosis. Compared to non-carriers, individuals with copy-neutral loss of heterozygosity mCAs had a significantly increased risk of cirrhosis (hazard ratio (HR) 1.42, 95% confidence interval (CI) 1.12-1.81). This risk was higher in patients with expanded cell fractions of mCAs (cell fractions ≥10% vs. cell fractions <10%), especially for the risk of decompensated cirrhosis (HR 2.03 [95% CI 1.09-3.78] vs. 1.14 [0.80-1.64]). In comparison to non-carriers of mCAs with low genetic risk, individuals with expanded copy-neutral loss of heterozygosity and high genetic risk showed the highest cirrhosis risk (HR 5.39 [95% CI 2.41-12.07]).
The presence of mCAs is associated with increased susceptibility to cirrhosis risk and could be combined with PRS for personalized cirrhosis risk stratification.
从血液来源DNA基因分型中检测到的与年龄相关的嵌合染色体改变(mCAs)是指示克隆性造血的结构体细胞变异。本研究旨在调查mCAs是否会增加肝硬化风险,并改变多基因风险评分(PRS)对肝硬化风险预测的影响。
从英国生物银行获取欧洲血统个体的mCA调用集。基于12个肝硬化易感单核苷酸多态性构建PRS。应用Cox比例风险模型评估mCAs与肝硬化风险之间的关联。
在448,645名个体中,中位随访时间为12.5年,我们确定了2,681例肝硬化病例,1,775例代偿期肝硬化病例和1,706例失代偿期肝硬化病例。与非携带者相比,杂合性mCAs拷贝中性缺失的个体患肝硬化的风险显著增加(风险比(HR)1.42,95%置信区间(CI)1.12 - 1.81)。mCAs细胞分数增加的患者(细胞分数≥10% 与细胞分数<10%)风险更高,尤其是失代偿期肝硬化风险(HR 2.03 [95% CI 1.09 - 3.78] 与1.14 [0.80 - 1.64])。与低遗传风险的mCAs非携带者相比,杂合性拷贝中性缺失且遗传风险高的个体肝硬化风险最高(HR 5.39 [95% CI 2.41 - 12.07])。
mCAs的存在与肝硬化风险易感性增加相关,可与PRS结合用于个性化的肝硬化风险分层。